US Patent 8182813 Human C-FMS antigen binding proteins
Patent 8182813 was granted and assigned to Amgen on May, 2012 by the United States Patent and Trademark Office.
All edits
Edits on 29 Mar, 2024
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 29 Nov, 2023
Golden AI
Edits made to:
Article (+362 characters)
Article
Patent abstract
Antigen binding proteins that bind to human c-fms protein are provided. Nucleic acids encoding the antigen binding protein, vectors, and cells encoding the same are also provided. The antigen binding proteins can inhibit binding of c-fms to CSF-1, reduce monocyte migration into tumors, and reduce the accumulation of tumor-associated macrophages.
Edits on 25 May, 2023
Golden AI
Edits made to:
Infobox (+1/-1 properties)
US Patent 08182813 Human C-FMS antigen binding proteins US Patent 8182813 Human C-FMS antigen binding proteins
Infobox
Patent Number
0818281300
Patent Number
818281300
Edits on 25 Apr, 2023
Golden AI
Infobox
Is a
Current Assignee
Patent Jurisdiction
Patent Number
081828130
Date of Patent
May 22, 2012
0Patent Application Number
121951690
Date Filed
August 20, 2008
0Patent Primary Examiner
Edits on 28 Sep, 2022
Golden AI
Infobox
Is a
Current Assignee
Patent Jurisdiction
Patent Number
081828130
Date of Patent
May 22, 2012
0Patent Application Number
121951690
Date Filed
August 20, 2008
0Patent Primary Examiner
Edits on 14 Dec, 2021
Golden AI
Edits made to:
Infobox (+8 properties)
US Patent 08182813 Human C-FMS antigen binding proteins
Infobox
Is a
Current assignee
Patent jurisdiction
Patent number
08182813
Date of patent
May 22, 2012
Patent application number
12195169
Date Filed
August 20, 2008
Patent primary examiner
Find more entities like US Patent 8182813 Human C-FMS antigen binding proteins
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
